03 Guías de Procedimientos en Ginecología (277)

Prévia do material em texto

Pág. 282
Guías de Procedimientos en Ginecología
Índices de supervivencia general (%)
Estadio 5 años
Ia1 94,6
Ia2 92,6
Ib1 80,7
Ib2 79,8
IIa 76
IIb 73,3
IIIa 50,5
IIIb 46,4
IVa 29,6
IVb 22
Bibliografía:
1. Whelan, S., Parkin, D., et al. Patterns of cancer on five continent. Lyon, France:
Intenational Agency for Research on Cancer, 1990.
2. Jemal, A., Tiwai, R., et al. Cancer statistics 2003. Cancer J Clinics, 2004; 54: 529
3. Walboomers, J., Jaikobs, M., et al. Human oapiloma virus. Necessary cause of invasive cervical cancer world
wide. J Pathol , 1999; 189: 1219
4. DiSaia, P. Oncología Ginecológica Clínica. Madrid, 1999. 5ta edición, Harcourt Brace.
5. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. National Cancer Institute
Workshop. JAMA 262 (7): 931-4, 1989
6. Landoni F, Maneo A, Colombo A, et al.: Randomised study of radical surgery versus radiotherapy for stage
Ib-IIa cervical cancer. Lancet 350 (1977): 535-40, 1997. 
7. NCI
8. Cunningham MJ, Dunton CJ, Corn B, et al.: Extended-field radiation therapy in early-stage cervical
carcinoma: survival and complications. Gynecol Oncol 43 (1): 51-4, 1991. 
9. Downey GO, Potish RA, Adcock LL, et al.: Pretreatment surgical staging in cervical carcinoma: therapeutic
efficacy of pelvic lymph node resection. Am J Obstet Gynecol 160: 1055-61, 1989
10. Keys HM, Bundy BN, Stehman FB, et al.: Cisplatin, radiation, and adjuvant hysterectomy compared with
radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.
N Engl J Med 340 (15): 1154-61, 1999
11. Thoms WW Jr, Eifel PJ, Smith TL, et al.: Bulky endocervical carcinoma: a 23-year experience.
Int J Radiat Oncol Biol Phys 23 (3): 491-9, 1992
12. Patel FD, Sharma SC, Negi PS, et al.: Low dose rate vs. high dose rate brachytherapy in the treatment of
carcinoma of the uterine cervix: a clinical trial. Int J Radiat Oncol Biol Phys 28 (2): 335-41, 1994. .
13. Hareyama M, Sakata K, Oouchi A, et al.: High-dose-rate versus low-dose-rate intracavitary therapy for
carcinoma of the uterine cervix: a randomized trial. Cancer 94 (1): 117-24, 20
14. Lertsanguansinchai P, Lertbutsayanukul C, Shotelersuk K, et al.: Phase III randomized trial comparing LDR
and HDR brachytherapy in treatment of cervical carcinoma. Int J Radiat Oncol Biol Phys 59 (5): 1424-31, 2004
15. Nag S, Chao C, Erickson B, et al.: The American Brachytherapy Society recommendations for low-dose-rate
brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 52 (1): 33-48, 2002. 
16. Nag S, Erickson B, Thomadsen B, et al.: The American Brachytherapy Society recommendations
for high-dose-rate brachytherapy for carcinoma of the cervix.
Int J Radiat Oncol Biol Phys 48 (1): 201-11, 2000.
17. Rose PG, Bundy BN, Watkins EB, et al.: Concurrent cisplatin-based radiotherapy and chemotherapy for
locally advanced cervical cancer. N Engl J Med 340 (15): 1144-53, 1999. 
18. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al.: Concurrent chemotherapy and pelvic radiation therapy compared
with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer
of the cervix. J Clin Oncol 18 (8): 1606-13, 2000
19. Thomas GM: Improved treatment for cervical cancer—concurrent chemotherapy and radiotherapy.
N Engl J Med 340 (15): 1198-200, 1999
20. Sardi, J., Giaroli, A.., et al. Long-term follow-up of the first randomized trial using neoadjuvant chem otherapy
in stage Ib squamous carcinoma of the cervix: the final results. Gynecol Oncol, 1997; 67:61-9
21. Sardi J., Sananes, C., et al. Results of a prospective randomized trial with neoadjuvant chemotherapy in stage
IB, bulky, squamous carcinoma of the cervix. Gynecol Oncol, 1993; 49:156-65